3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial

Stahel, R.; Dafni, Urania; Gautschi, Oliver; Felip, Enriqueta; Curioni-Fontecedro, Alessandra; Peters, S.; Massutí, B.; Cardenal, F.; Aix, S Ponce; Früh, Martin; Pless, Miklos; Popat, Sanjay; Kotsakis, A.; Cuffe, Sinéad; Bidoli, Paolo; Favaretto, Adolfo; Carcereny, Enric; Ronco, M. Sanchez; Molina, M.A.; Rosell, R.

doi:10.1016/s0959-8049(15)30068-x

Cited by 31 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary endpoints are toxicity and disease-free survival. 6 is a randomized phase II study of erlotinib alone or combined with bevacizumab in EGFRmutant NSCLC. Patients without brain metastases and without previous chemotherapy or tyrosine kinase inhibitor treatment will be randomized to erlotinib alone or erlotinib with bevacizumab.…”

Section: Alliance For Clinical Trials In Oncologymentioning

confidence: 99%

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy

Shukla

Salahudeen

Taylor

et al. 2018

Clinical Lung Cancer

View full text Add to dashboard Cite

Cancer cooperative groups have historically played a critical role in the advancement of nonesmall-cell lung cancer therapy. Representatives from cooperative groups worldwide convene at the International Lung Cancer Congress annually. The International Lung Cancer Congress had its 17th anniversary in the summer of 2016. The present review highlights the thoracic malignancy studies discussed by presenters. The included studies are merely a sample of the trials of thoracic malignancies ongoing globally.

show abstract

Section: Alliance For Clinical Trials In Oncologymentioning

confidence: 99%

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy

Shukla

Salahudeen

Taylor

et al. 2018

Clinical Lung Cancer

View full text Add to dashboard Cite

show abstract

“…A European single-arm phase II trial of bevacizumab-erlotinib (BELIEF; ETOP 2-11) in EGFR common mutations demonstrated a less impressive median PFS of 13.8 months, with no difference in outcome between del19 or L858R, but more prolonged PFS in those with T790M detected at baseline by an ultrasensitive method (PCR-PNA) than without (16 versus 10.5 months, respectively) [Stahel et al 2015]. The European Medicines Agency (EMA) has recently approved this combination and a confirmatory randomized European trial is recruiting (BEVERLY [ClinicalTrials.gov identifier: NCT02633189]).…”

Section: Can We Delay the Development Of Acquired Resistance To Firstmentioning

confidence: 99%

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications

Juan

Popat

2017

Ther Adv Med Oncol

View full text Add to dashboard Cite

Discovery of sensitizing mutations in epidermal growth factor receptor (EGFR) and the subsequent development of EGFR tyrosine kinase inhibitors (TKIs) have substantially changed the treatment of lung cancer. First-line treatment with EGFR TKIs (gefitinib, erlotinib and afatinib) has demonstrated a superior response rate and progression-free survival (PFS) compared with chemotherapy in EGFR-mutation positive patients. However, a number of open questions remain, such as choice between the three EGFR TKIs licensed, treatment of patients unsuitable for chemotherapy due to morbidity or advanced age, management of acquired resistance and optimal biological sample to determine EGFR status. Recently the first headto-head trial comparing gefitinib and afatinib (LUX-Lung 7) has been reported. Moreover, third-generation EGFR TKIs such as osimertinib, rociletinib, olmutinib and ASP8273, with preferential activity against T790M mutant tumours, the commonest resistance mechanism to EGFR TKIs, have shown promising results in early clinical trials, with osimertinib now licensed. In this review, we summarize latest advances in the treatment of EGFR-mutation positive patients focusing on controversial areas and emerging challenges to optimally treat these patients in the future.

show abstract

“…The results of such study showed a significant longer median PFS (16 vs 9.7 months), with about 50% reduction of the risk of progression (HR: 0.54 (95%CI: 0.36-0.79)) in favour of the combination arm (Seto et al, 2014). Interestingly the preliminary results of the European BELIEF trial have recently revealed that patients with EGFR-T790M positive tumors would benefit more from erlotinib plus bevacizumab combination with a median PFS of 16 months compared to 10.5 months of patients without T790M, suggesting a new potential strategy to overcome T790M-mediated acquired resistance (Stahel et al, 2015). The major concern for clinical use is represented by the cumulative toxicity, whit about 60% of G3-4 hypertension and 8% of G3-4 proteinuria reported in the combination arm, while no differences in drug-discontinuation rate have been observed between the two treatments.…”

Section: Anti-angiogenic Agentsmentioning

confidence: 99%

EGFR inhibition in NSCLC: New findings…. and opened questions?

Passiglia

Listì

Castiglia

et al. 2017

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent findings regarding EGFR-inhibition in NSCLC, highlighting the current unsolved questions on the selection of the best TKI in first-line, which therapy can be combined with upfront EGFR-TKIs, how to overcome acquired resistance, and which are the clinical applications of liquid biopsy

show abstract

Cited by 31 publications

References 0 publications

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications

EGFR inhibition in NSCLC: New findings…. and opened questions?

Contact Info

Product

Resources

About